A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer
- 84 Downloads
Pancreatic cancer is a malignant tumor of the digestive system with poor prognosis and high mortality, and the treatment of pancreatic cancer still remains a major challenge. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis selectively in cancer cells while causing virtually no damage to normal cells, which is promising for cancer therapy. However, many primary tumors and cancer cell lines including various human pancreatic cancer cell lines were found to be resistant to TRAIL-induced apoptosis. Therefore, the purpose of the study was to improve antitumor effect of TRAIL on pancreatic cancer.
The 114–121 amino acid coding sequence “VRERGPQR” of wild type TRAIL protein that was selected changed into “RRRRRRRR”, and the novel membrane-penetrating peptide-alike mutant protein was named TRAIL-Mu3. The antitumor effect of TRAIL-Mu3 was analyzed both in vitro and in vivo. Western blotting, immunofluorescence and flow cytometry were used to investigate the underlying mechanisms.
TRAIL-Mu3 could enhance the antitumor effects on pancreatic cancer cell lines, and the antitumor effect of TRAIL-Mu3 was stronger than gemcitabine in vivo. The immunofluorescence results suggested that TRAIL-Mu3 could remarkably enhance the affinity to pancreatic cancer cells. The Western blot results showed that treatment with TRAIL-Mu3 caused a clear cleavage of caspase-3 and caspase-8. In addition, both the Western blot and flow cytometry suggested a significantly up-expression of DR5 in TRAIL-Mu3 group.
Membrane-penetrating peptide-alike mutant-TRAIL-Mu3 induced pancreatic cancer cell death more efficiently than TRAIL, and this effect was supposed to be mediated by the increased affinity to cell membrane, the up-regulation of DR5 and the enhancement of activated caspase.
KeywordsTRAIL DR4/DR5 TRAIL mutant membrane-penetrating peptide-alike (TMPPA) Apoptosis Pancreatic cancer
We thank Chengdu Huachuang Biotechnology Co., Ltd. for expert technical assistance.
This work was supported by Grants from the National Natural Scientific Foundation of China (No. 81301962 and No. 81372444).
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 1.Han Y, Park S, Kinyua AW, Andera L, Kim KW, Kim I (2014) Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein. Oncol Rep 31(1):456–462. https://doi.org/10.3892/or.2013.2838 CrossRefPubMedGoogle Scholar
- 2.Recio-Boiles A, Ilmer M, Rhea PR, Kettlun C, Heinemann ML, Ruetering J, Vykoukal J, Alt E (2016) JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells. Oncotarget 7(9):9890–9906. https://doi.org/10.18632/oncotarget.7066 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials G (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15):1960–1966. https://doi.org/10.1200/JCO.2006.07.9525 CrossRefPubMedGoogle Scholar
- 5.Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27(13):2231–2237. https://doi.org/10.1200/JCO.2008.20.0238 CrossRefPubMedGoogle Scholar
- 15.Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, Kolligs FT, Kirchner T, Goke B, De Toni EN (2010) Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 16(22):5529–5538. https://doi.org/10.1158/1078-0432.CCR-09-3403 CrossRefPubMedGoogle Scholar
- 16.Tanaka R, Tomosugi M, Horinaka M, Sowa Y, Sakai T (2015) Metformin causes G1-phase arrest via down-regulation of MiR-221 and enhances TRAIL sensitivity through DR5 up-regulation in pancreatic cancer cells. PLoS One 10(5):e0125779. https://doi.org/10.1371/journal.pone.0125779 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299(1):31–38PubMedGoogle Scholar
- 20.Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1):S86–S96. https://doi.org/10.1038/sj.cdd.4401437 CrossRefPubMedGoogle Scholar
- 23.Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12(8):2640–2646. https://doi.org/10.1158/1078-0432.CCR-05-2635 CrossRefPubMedGoogle Scholar
- 24.Gallego-Lleyda A, De Miguel D, Anel A, Martinez-Lostao L (2018) Lipid nanoparticles decorated with TNF-related apoptosis-inducing ligand (TRAIL) are more cytotoxic than soluble recombinant TRAIL in sarcoma. Int J Mol Sci 19(5):1449. https://doi.org/10.3390/ijms19051449 CrossRefPubMedCentralGoogle Scholar
- 25.Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Rocken C, Gluer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A (2018) The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis 9(5):445. https://doi.org/10.1038/s41419-018-0478-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 104(24):10152–10157. https://doi.org/10.1073/pnas.0702916104 CrossRefPubMedGoogle Scholar
- 27.Li R, Yang H, Jia D, Nie Q, Cai H, Fan Q, Wan L, Li L, Lu X (2016) Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release 228:96–106. https://doi.org/10.1016/j.jconrel.2016.03.004 CrossRefPubMedGoogle Scholar
- 29.van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 103(23):8634–8639. https://doi.org/10.1073/pnas.0510187103 CrossRefPubMedGoogle Scholar